12h
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the ...
The FDA has authorized urcosimod 0.05% for single-patient expanded access, or compassionate use, in a patient with ...
FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and ...
A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...
DelveInsight's Persistent Corneal Edema Market Insights report includes a comprehensive understanding of current treatment ...
LONDON and NEW YORK, Jan. 23, 2026), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseas ...
Eric Donnenfeld’s corneal health case presentations and panel discussion at OSN New York are always popular with meeting ...
SIOUX FALLS, SD - January 23, 2026 - PRESSADVANTAGE - Vance Thompson Vision is drawing attention to its advanced ...
EyeYon Medical says FDA granted IDE for a multicenter study led by Scripps Clinic’s Prof. Francis Mah, with enrollment ...
If you were to listen to a day in the life of a veterinary ophthalmologist, you’d likely hear words and phrases you’ve never heard before. “A tubing system will be placed under your horse’s eyelid to ...
2d
Kugler Vision Publishes SMILE vs LASIK Comparison for Patients Exploring Vision Correction Options
OMAHA, NE - January 21, 2026 - PRESSADVANTAGE - Kugler Vision has released a new educational article titled "SMILE vs ...
PLANO, TX - January 13, 2026 - PRESSADVANTAGE - A newly released article titled “LASIK Results in Dallas–Fort Worth: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback